Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human TNFRSF10D Antibodies:
anti-Mouse (Murine) TNFRSF10D Antibodies:
anti-Rat (Rattus) TNFRSF10D Antibodies:
Go to our pre-filtered search.
Human Polyclonal TNFRSF10D Primary Antibody for ELISA, ICC - ABIN4361837
Mitsiades, Poulaki, Tseleni-Balafouta, Koutras, Stamenkovic: Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. in Cancer research 2000
Show all 19 Pubmed References
Human Monoclonal TNFRSF10D Primary Antibody for CyTOF, ELISA (Capture) - ABIN4900417
Barbarotto, Corallini, Rimondi, Fadda, Mischiati, Grill, Vaccarezza, Celeghini: Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. in Journal of cellular biochemistry 2008
Show all 13 Pubmed References
Human Monoclonal TNFRSF10D Primary Antibody for FACS - ABIN4897669
Stary, Klein, Kohlhofer, Koszik, Scherzer, Müllauer, Quendler, Kohrgruber, Stingl: Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. in Blood 2009
Show all 11 Pubmed References
Human Polyclonal TNFRSF10D Primary Antibody for CyTOF, FACS - ABIN4900418
Zauli, Pandolfi, Gonelli, Di Pietro, Guarnieri, Ciabattoni, Rana, Vitale, Secchiero: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. in Circulation research 2003
Show all 6 Pubmed References
Human Monoclonal TNFRSF10D Primary Antibody for ICC, FACS - ABIN1169231
Washburn, Weigand, Grosse-Wilde, Janke, Stahl, Rieser, Sprick, Schirrmacher, Walczak: TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. in Journal of immunology (Baltimore, Md. : 1950) 2003
Show all 3 Pubmed References
Human Monoclonal TNFRSF10D Primary Antibody for FACS - ABIN1383933
Baritaki, Katsman, Chatterjee, Yeung, Spandidos, Bonavida: Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. in Journal of immunology (Baltimore, Md. : 1950) 2007
Show all 2 Pubmed References
Human Monoclonal TNFRSF10D Primary Antibody for FACS - ABIN1383934
Vermot-Desroches, Sergent, Bonnin, Wijdenes: Characterization of monoclonal antibodies directed against trail or trail receptors. in Cellular immunology 2005
Human Monoclonal TNFRSF10D Primary Antibody for - ABIN1383749
Mérino, Lalaoui, Morizot, Schneider, Solary, Micheau: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. in Molecular and cellular biology 2006
Urinary DcR2 (show CCR6 Antibodies) could potentially serve as a novel biomarker for tubulointerstitial injury and may reflect senescence of renal proximal tubular cells in diabetic nephropathy.
Results identified epigenetic inactivation of TNFRSF10C (show TNFRSF10C Antibodies) and TNFRSF10D in majority of cervical cancer cases.
This study identified TNFRSF10D DNA methylation (show HELLS Antibodies) status as an independent prognostic biomarker for relapse-free survival and overall mortality in non-metastatic melanoma patients.
The membrane expression of the TRAIL receptors DR4 (show HLADRB4 Antibodies), DR5 (show TNFRSF10B Antibodies), DcR1 (show TNFRSF10C Antibodies) and DcR2 (show CCR6 Antibodies) is greater in normal endometrium than endometrioid adenocarcinoma (EAC (show CYLD Antibodies)). The level of the receptors in EAC (show CYLD Antibodies) is not dependent on grading and staging and does not predict survival.
the results presented here claim for a relevant impact of aberrant methylation of decoy receptors in melanoma and allow to understand how the silencing of DcR1 (show TNFRSF10C Antibodies) and DcR2 (show CCR6 Antibodies) is related to melanomagenesis.
transcript levels of UCHL1 (show UCHL1 Antibodies), COL1A2 (show COL1A2 Antibodies), THBS1 (show THBS1 Antibodies) and TNFRSF10D were inversely correlated with promoter methylation
TRAIL receptor-4 expression profiles on T cells might be important in revelation of rheumatoid arthritis pathogenesis.
ANT2 (show SLC25A5 Antibodies) shRNA treatment sensitized MCF7, T47 D, and BT474 cells to TRAIL-induced apoptosis by up-regulating the expression of TRAIL death receptors 4 and 5 (DR4 (show HLADRB4 Antibodies) and DR5 (show TNFRSF10B Antibodies)) and down-regulating the TRAIL decoy receptor 2 (DcR2).
these results demonstrated that hypoxia-inducible factor 1alpha played a crucial role in regulating the transcription of DcR2 (show CCR6 Antibodies).
TNF-related apoptosis-inducing ligand (TRAIL (show TNFSF10 Antibodies)) is not constitutively expressed in the human brain, whereas both apoptosis-mediating and apoptosis-blocking TRAIL receptors are found on neurons, astrocytes, and oligodendrocytes
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis.
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain
, TNF receptor-related receptor for TRAIL
, TNF-related apoptosis-inducing ligand receptor 4
, TRAIL receptor 4
, TRAIL receptor with a truncated death domain
, decoy receptor 2
, tumor necrosis factor receptor superfamily member 10D